Flow diagram of the validation process for the combined Nanobody ELISA.
<p>Human serum samples were collected at Orán Hospital, Salta (2016–2019) and classified by a reference diagnostic test (positive, n=94; negative, n=74). Samples were analyzed using the cNb-ELISA, and results were subjected to statistical validation. Diagnostic validation included ROC curve an...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852015241361096704 |
|---|---|
| author | María Florencia Pavan (22538063) |
| author2 | Cristian Miguel Malnero (22538066) María Emilia Mora Alvarado (22538069) María Camila Carzoglio (22538072) Yesica Paredes Rojas (22538075) Agostina Bruno (9708143) Laura Perez Vidakovics (14372943) Leo Hanke (14245409) Alejandro Castello (11822201) Gerald McInerney (167172) Cybele Carina García (22538078) Viviana Parreño (409570) Lorena Itatí Ibañez (22538081) |
| author2_role | author author author author author author author author author author author author |
| author_facet | María Florencia Pavan (22538063) Cristian Miguel Malnero (22538066) María Emilia Mora Alvarado (22538069) María Camila Carzoglio (22538072) Yesica Paredes Rojas (22538075) Agostina Bruno (9708143) Laura Perez Vidakovics (14372943) Leo Hanke (14245409) Alejandro Castello (11822201) Gerald McInerney (167172) Cybele Carina García (22538078) Viviana Parreño (409570) Lorena Itatí Ibañez (22538081) |
| author_role | author |
| dc.creator.none.fl_str_mv | María Florencia Pavan (22538063) Cristian Miguel Malnero (22538066) María Emilia Mora Alvarado (22538069) María Camila Carzoglio (22538072) Yesica Paredes Rojas (22538075) Agostina Bruno (9708143) Laura Perez Vidakovics (14372943) Leo Hanke (14245409) Alejandro Castello (11822201) Gerald McInerney (167172) Cybele Carina García (22538078) Viviana Parreño (409570) Lorena Itatí Ibañez (22538081) |
| dc.date.none.fl_str_mv | 2025-10-31T17:58:26Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pntd.0013168.s016 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Flow_diagram_of_the_validation_process_for_the_combined_Nanobody_ELISA_/30504995 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Genetics Biotechnology Cancer Infectious Diseases Virology Computational Biology system exhibits limitations successfully identified cases sera pool dilutions public health system cases increasing sharply borne flavivirus responsible target ns1 across reported ns1 concentrations precision diagnostic tools 3 &# 8211 four denv serotypes denv genome encodes structural protein 1 6 &# 8211 early infection detection ns1 ), diagnostic sensitivity detecting ns1 3 %). denv ), xlink "> urgent need symptom onset sporadic disease results underscore regions facing recurrent epidemic recent decades limited access key biomarker human samples exposing gaps engineered nanobodies detection antibodies detection aligning detected signals affecting 18 accurate diagnosis 9 ), 6 %) 23 provinces |
| dc.title.none.fl_str_mv | Flow diagram of the validation process for the combined Nanobody ELISA. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Human serum samples were collected at Orán Hospital, Salta (2016–2019) and classified by a reference diagnostic test (positive, n=94; negative, n=74). Samples were analyzed using the cNb-ELISA, and results were subjected to statistical validation. Diagnostic validation included ROC curve analysis (sensitivity, specificity, AUC, and cut-off determination), followed by assessment of diagnostic performance (sensitivity, specificity, Cohen’s kappa agreement, and DIA-PRO analysis for discordant samples). Analytical validation included determination of sensitivity and limit of detection (LOD).</p> <p>(TIF)</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_de8cd9932cb1ef04fff46b641b4e188d |
| identifier_str_mv | 10.1371/journal.pntd.0013168.s016 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30504995 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Flow diagram of the validation process for the combined Nanobody ELISA.María Florencia Pavan (22538063)Cristian Miguel Malnero (22538066)María Emilia Mora Alvarado (22538069)María Camila Carzoglio (22538072)Yesica Paredes Rojas (22538075)Agostina Bruno (9708143)Laura Perez Vidakovics (14372943)Leo Hanke (14245409)Alejandro Castello (11822201)Gerald McInerney (167172)Cybele Carina García (22538078)Viviana Parreño (409570)Lorena Itatí Ibañez (22538081)MedicineGeneticsBiotechnologyCancerInfectious DiseasesVirologyComputational Biologysystem exhibits limitationssuccessfully identified casessera pool dilutionspublic health systemcases increasing sharplyborne flavivirus responsibletarget ns1 acrossreported ns1 concentrationsprecision diagnostic tools3 &# 8211four denv serotypesdenv genome encodesstructural protein 16 &# 8211early infection detectionns1 ),diagnostic sensitivitydetecting ns13 %).denv ),xlink ">urgent needsymptom onsetsporadic diseaseresults underscoreregions facingrecurrent epidemicrecent decadeslimited accesskey biomarkerhuman samplesexposing gapsengineered nanobodiesdetection antibodiesdetection aligningdetected signalsaffecting 18accurate diagnosis9 ),6 %)23 provinces<p>Human serum samples were collected at Orán Hospital, Salta (2016–2019) and classified by a reference diagnostic test (positive, n=94; negative, n=74). Samples were analyzed using the cNb-ELISA, and results were subjected to statistical validation. Diagnostic validation included ROC curve analysis (sensitivity, specificity, AUC, and cut-off determination), followed by assessment of diagnostic performance (sensitivity, specificity, Cohen’s kappa agreement, and DIA-PRO analysis for discordant samples). Analytical validation included determination of sensitivity and limit of detection (LOD).</p> <p>(TIF)</p>2025-10-31T17:58:26ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pntd.0013168.s016https://figshare.com/articles/figure/Flow_diagram_of_the_validation_process_for_the_combined_Nanobody_ELISA_/30504995CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/305049952025-10-31T17:58:26Z |
| spellingShingle | Flow diagram of the validation process for the combined Nanobody ELISA. María Florencia Pavan (22538063) Medicine Genetics Biotechnology Cancer Infectious Diseases Virology Computational Biology system exhibits limitations successfully identified cases sera pool dilutions public health system cases increasing sharply borne flavivirus responsible target ns1 across reported ns1 concentrations precision diagnostic tools 3 &# 8211 four denv serotypes denv genome encodes structural protein 1 6 &# 8211 early infection detection ns1 ), diagnostic sensitivity detecting ns1 3 %). denv ), xlink "> urgent need symptom onset sporadic disease results underscore regions facing recurrent epidemic recent decades limited access key biomarker human samples exposing gaps engineered nanobodies detection antibodies detection aligning detected signals affecting 18 accurate diagnosis 9 ), 6 %) 23 provinces |
| status_str | publishedVersion |
| title | Flow diagram of the validation process for the combined Nanobody ELISA. |
| title_full | Flow diagram of the validation process for the combined Nanobody ELISA. |
| title_fullStr | Flow diagram of the validation process for the combined Nanobody ELISA. |
| title_full_unstemmed | Flow diagram of the validation process for the combined Nanobody ELISA. |
| title_short | Flow diagram of the validation process for the combined Nanobody ELISA. |
| title_sort | Flow diagram of the validation process for the combined Nanobody ELISA. |
| topic | Medicine Genetics Biotechnology Cancer Infectious Diseases Virology Computational Biology system exhibits limitations successfully identified cases sera pool dilutions public health system cases increasing sharply borne flavivirus responsible target ns1 across reported ns1 concentrations precision diagnostic tools 3 &# 8211 four denv serotypes denv genome encodes structural protein 1 6 &# 8211 early infection detection ns1 ), diagnostic sensitivity detecting ns1 3 %). denv ), xlink "> urgent need symptom onset sporadic disease results underscore regions facing recurrent epidemic recent decades limited access key biomarker human samples exposing gaps engineered nanobodies detection antibodies detection aligning detected signals affecting 18 accurate diagnosis 9 ), 6 %) 23 provinces |